Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick F Fogarty

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Seminars in Hematology|January 26, 2016
Hemophilia in the 21st century: tremendous progress, tremendous opportunityPatrick F Fogarty
Hematology. American Society of Hematology. Education Program|December 14, 2011
Biological rationale for new drugs in the bleeding disorders pipelinePatrick F Fogarty
Blood|December 14, 2011
ITP: tolerance lostPatrick F Fogarty
Hematology/Oncology Clinics of North America|November 26, 2009
Chronic immune thrombocytopenia in adults: epidemiology and clinical presentationPatrick F Fogarty
The Medical Clinics of North America|February 27, 2008
Diagnosis and management of venous thromboembolismTracy Minichiello, Patrick F Fogarty
Hematology. American Society of Hematology. Education Program|December 14, 2011
What is the evidence for the use of immunomodulatory agents to eradicate inhibitory antibodies in patients with severe hemophilia a who have previously failed to respond to immune tolerance induction?Michael U Callaghan, Patrick F Fogarty
Current Opinion in Hematology|October 16, 2007
The epidemiology of immune thrombocytopenic purpuraPatrick F Fogarty, Jodi B Segal
Seminars in Hematology|January 26, 2016
Gene therapy for hemophilia: past, present and futureLindsey A George, Patrick F Fogarty
Clinical Advances in Hematology & Oncology : H&O|October 21, 2005
Resetting the immune system in immune thrombocytopenic purpura: immunoablative strategiesPatrick F Fogarty, Cynthia E Dunbar
Drugs - Real World Outcomes|September 1, 2025
Clinical Burden and Healthcare Resource Use Among Adults Living with Hemophilia A: An Observational StudyLisa Young, Lu Ban, Yong Chen, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Seminars in Hematology|January 26, 2016
Hemophilia in the 21st century: tremendous progress, tremendous opportunityPatrick F Fogarty
Hematology. American Society of Hematology. Education Program|December 14, 2011
Biological rationale for new drugs in the bleeding disorders pipelinePatrick F Fogarty
Blood|December 14, 2011
ITP: tolerance lostPatrick F Fogarty
Hematology/Oncology Clinics of North America|November 26, 2009
Chronic immune thrombocytopenia in adults: epidemiology and clinical presentationPatrick F Fogarty
The Medical Clinics of North America|February 27, 2008
Diagnosis and management of venous thromboembolismTracy Minichiello, Patrick F Fogarty
Hematology. American Society of Hematology. Education Program|December 14, 2011
What is the evidence for the use of immunomodulatory agents to eradicate inhibitory antibodies in patients with severe hemophilia a who have previously failed to respond to immune tolerance induction?Michael U Callaghan, Patrick F Fogarty
Current Opinion in Hematology|October 16, 2007
The epidemiology of immune thrombocytopenic purpuraPatrick F Fogarty, Jodi B Segal
Seminars in Hematology|January 26, 2016
Gene therapy for hemophilia: past, present and futureLindsey A George, Patrick F Fogarty
Clinical Advances in Hematology & Oncology : H&O|October 21, 2005
Resetting the immune system in immune thrombocytopenic purpura: immunoablative strategiesPatrick F Fogarty, Cynthia E Dunbar
Drugs - Real World Outcomes|September 1, 2025
Clinical Burden and Healthcare Resource Use Among Adults Living with Hemophilia A: An Observational StudyLisa Young, Lu Ban, Yong Chen, et al.
Pageof 3